IBDEI04S ; ; 12-AUG-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;MAY 15, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1971,1,5,0)
 ;;=5^HX OF KIDNEY MALIGNANCY
 ;;^UTILITY(U,$J,358.3,1971,2)
 ;;=^295229
 ;;^UTILITY(U,$J,358.3,1972,0)
 ;;=V10.53^^21^187^15
 ;;^UTILITY(U,$J,358.3,1972,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1972,1,4,0)
 ;;=4^V10.53
 ;;^UTILITY(U,$J,358.3,1972,1,5,0)
 ;;=5^HX OF MAL NEOPLASM,RENAL PELVIS
 ;;^UTILITY(U,$J,358.3,1972,2)
 ;;=^323624
 ;;^UTILITY(U,$J,358.3,1973,0)
 ;;=V10.59^^21^187^45
 ;;^UTILITY(U,$J,358.3,1973,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1973,1,4,0)
 ;;=4^V10.59
 ;;^UTILITY(U,$J,358.3,1973,1,5,0)
 ;;=5^HX-URINARY MALIGNAN NEC
 ;;^UTILITY(U,$J,358.3,1973,2)
 ;;=^295230
 ;;^UTILITY(U,$J,358.3,1974,0)
 ;;=V10.60^^21^187^12
 ;;^UTILITY(U,$J,358.3,1974,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1974,1,4,0)
 ;;=4^V10.60
 ;;^UTILITY(U,$J,358.3,1974,1,5,0)
 ;;=5^HX OF LEUKEMIA NOS
 ;;^UTILITY(U,$J,358.3,1974,2)
 ;;=^295231
 ;;^UTILITY(U,$J,358.3,1975,0)
 ;;=V10.61^^21^187^14
 ;;^UTILITY(U,$J,358.3,1975,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1975,1,4,0)
 ;;=4^V10.61
 ;;^UTILITY(U,$J,358.3,1975,1,5,0)
 ;;=5^HX OF LYMPHOID LEUKEMIA
 ;;^UTILITY(U,$J,358.3,1975,2)
 ;;=^295232
 ;;^UTILITY(U,$J,358.3,1976,0)
 ;;=V10.62^^21^187^18
 ;;^UTILITY(U,$J,358.3,1976,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1976,1,4,0)
 ;;=4^V10.62
 ;;^UTILITY(U,$J,358.3,1976,1,5,0)
 ;;=5^HX OF MYELOID LEUKEMIA
 ;;^UTILITY(U,$J,358.3,1976,2)
 ;;=^295233
 ;;^UTILITY(U,$J,358.3,1977,0)
 ;;=V10.63^^21^187^17
 ;;^UTILITY(U,$J,358.3,1977,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1977,1,4,0)
 ;;=4^V10.63
 ;;^UTILITY(U,$J,358.3,1977,1,5,0)
 ;;=5^HX OF MONOCYTIC LEUKEMIA
 ;;^UTILITY(U,$J,358.3,1977,2)
 ;;=^295234
 ;;^UTILITY(U,$J,358.3,1978,0)
 ;;=V10.69^^21^187^11
 ;;^UTILITY(U,$J,358.3,1978,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1978,1,4,0)
 ;;=4^V10.69
 ;;^UTILITY(U,$J,358.3,1978,1,5,0)
 ;;=5^HX OF LEUKEMIA NEC
 ;;^UTILITY(U,$J,358.3,1978,2)
 ;;=^295235
 ;;^UTILITY(U,$J,358.3,1979,0)
 ;;=V10.71^^21^187^32
 ;;^UTILITY(U,$J,358.3,1979,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1979,1,4,0)
 ;;=4^V10.71
 ;;^UTILITY(U,$J,358.3,1979,1,5,0)
 ;;=5^HX-LYMPHOSARCOMA
 ;;^UTILITY(U,$J,358.3,1979,2)
 ;;=^295236
 ;;^UTILITY(U,$J,358.3,1980,0)
 ;;=V10.72^^21^187^28
 ;;^UTILITY(U,$J,358.3,1980,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1980,1,4,0)
 ;;=4^V10.72
 ;;^UTILITY(U,$J,358.3,1980,1,5,0)
 ;;=5^HX-HODGKIN'S DISEASE
 ;;^UTILITY(U,$J,358.3,1980,2)
 ;;=^295237
 ;;^UTILITY(U,$J,358.3,1981,0)
 ;;=V10.79^^21^187^31
 ;;^UTILITY(U,$J,358.3,1981,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1981,1,4,0)
 ;;=4^V10.79
 ;;^UTILITY(U,$J,358.3,1981,1,5,0)
 ;;=5^HX-LYMPHATIC MALIGN NEC
 ;;^UTILITY(U,$J,358.3,1981,2)
 ;;=^295238
 ;;^UTILITY(U,$J,358.3,1982,0)
 ;;=V10.81^^21^187^2
 ;;^UTILITY(U,$J,358.3,1982,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1982,1,4,0)
 ;;=4^V10.81
 ;;^UTILITY(U,$J,358.3,1982,1,5,0)
 ;;=5^HX OF BONE MALIGNANCY
 ;;^UTILITY(U,$J,358.3,1982,2)
 ;;=^295239
 ;;^UTILITY(U,$J,358.3,1983,0)
 ;;=V10.82^^21^187^35
 ;;^UTILITY(U,$J,358.3,1983,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1983,1,4,0)
 ;;=4^V10.82
 ;;^UTILITY(U,$J,358.3,1983,1,5,0)
 ;;=5^HX-MALIG SKIN MELANOMA
 ;;^UTILITY(U,$J,358.3,1983,2)
 ;;=^295240
 ;;^UTILITY(U,$J,358.3,1984,0)
 ;;=V10.83^^21^187^42
 ;;^UTILITY(U,$J,358.3,1984,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1984,1,4,0)
 ;;=4^V10.83
 ;;^UTILITY(U,$J,358.3,1984,1,5,0)
 ;;=5^HX-SKIN MALIGNANCY NEC
 ;;^UTILITY(U,$J,358.3,1984,2)
 ;;=^295241
 ;;^UTILITY(U,$J,358.3,1985,0)
 ;;=V10.84^^21^187^6
 ;;^UTILITY(U,$J,358.3,1985,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,1985,1,4,0)
 ;;=4^V10.84
